Oculis SA, a global biopharmaceutical company that develops treatments for saving sight and improving eye ... glaucoma. Other developments in the ophthalmic sector this year included the Alcon ...

Glaucoma is a leading cause of irreversible blindness ... In the laser-induced COH model, IOP measurements were performed on awake mice without any eye drops, whereas measurements were conducted on ...

The exclusion criteria included patients with other ocular co-morbidities (keratoconus, glaucoma, dry eye, diabetic retinopathy ... Germany (13)]} and a drop-out rate of 10%, the sample included 46 ...

It is the most common type of glaucoma, a set of eye diseases that affect the eye's optic nerve. The optic nerve is located ...

As the adage goes, the eyes are the windows to the soul. The answer is a hard no, according to the American Academy of Ophthalmology, which recently issued a warning against "eye color-changing ...

allows Alcon to expand its presence in the growing glaucoma market. The submission of AR-15512 for dry-eye treatment approval could open up a new revenue stream in the therapeutic eye care segment.

Quality of life in glaucoma patients can best be determined using the NEI-VFQ-25 and visual acuity evaluations.

Thus, this combined procedure could be potentially cost-saving, as majority of glaucoma patients are diagnosed at the earlier stage of the disease and are likely to be on eye drops for a prolonged ...

At EyeCon 2024, Analisa Arosemena, MD, discussed the shift away from traditional topical therapies towards more proactive ...

smoking and strong myopia), ocular comorbidities (including dry eye, allergy, cataract and age-related macular degeneration [ARMD]), and glaucoma history (duration, mode of discovery and family ...